Literature DB >> 23859507

[PD-1 and PDL-1 expression in cancer: significance and prognostic value].

Cécile Badoual, Pierre Combe, Alain Gey, Clémence Granier, Hélène Roussel, Eléonore De Guillebon, Stéphane Oudard, Eric Tartour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23859507     DOI： 10.1051/medsci/2013296005

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN： 0767-0974            Impact factor:   0.818


× No keyword cloud information.
  5 in total

1.  The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.

Authors:  Xiaolong Tang; Qingguo Li; Yongqiang Zhu; Donghui Zheng; Jingjing Dai; Wenxuan Ni; Jia Wei; Yubao Xue; Ke Chen; Wei Hou; Chao Zhang; Xiaojun Feng; Yong Liang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

2.  Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.

Authors:  Yi Zheng; Yicheng Yang; Shu Wu; Yongqiang Zhu; Xiaolong Tang; Xiaopeng Liu
Journal:  Bioengineered       Date:  2016-10-18       Impact factor: 3.269

Review 3.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

4.  Anti program death-1/anti program death-ligand 1 in digestive cancers.

Authors:  Eléonore de Guillebon; Pauline Roussille; Eric Frouin; David Tougeron
Journal:  World J Gastrointest Oncol       Date:  2015-08-15

5.  Hypoxia Selectively Impairs CAR-T Cells In Vitro.

Authors:  Robert Berahovich; Xianghong Liu; Hua Zhou; Elias Tsadik; Shirley Xu; Vita Golubovskaya; Lijun Wu
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.